JP2016537410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537410A5 JP2016537410A5 JP2016551080A JP2016551080A JP2016537410A5 JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5 JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016551080 A JP2016551080 A JP 2016551080A JP 2016537410 A5 JP2016537410 A5 JP 2016537410A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- oligosaccharide
- gos
- management
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 229920001542 oligosaccharide Polymers 0.000 claims 3
- 239000006041 probiotic Substances 0.000 claims 3
- 230000000529 probiotic effect Effects 0.000 claims 3
- 235000018291 probiotics Nutrition 0.000 claims 3
- 230000001580 bacterial effect Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- 235000013406 prebiotics Nutrition 0.000 claims 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940126534 drug product Drugs 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- -1 oligosaccharide galactooligosaccharides Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1319539.1 | 2013-11-05 | ||
| GBGB1319539.1A GB201319539D0 (en) | 2013-11-05 | 2013-11-05 | Composition & methods of screening |
| PCT/GB2014/053303 WO2015067949A1 (en) | 2013-11-05 | 2014-11-05 | Composition & methods of screening |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109634A Division JP2019206528A (ja) | 2013-11-05 | 2019-06-12 | 組成物およびスクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537410A JP2016537410A (ja) | 2016-12-01 |
| JP2016537410A5 true JP2016537410A5 (cg-RX-API-DMAC7.html) | 2018-06-14 |
| JP6890972B2 JP6890972B2 (ja) | 2021-06-18 |
Family
ID=49767702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551080A Active JP6890972B2 (ja) | 2013-11-05 | 2014-11-05 | 組成物およびスクリーニング方法 |
| JP2019109634A Pending JP2019206528A (ja) | 2013-11-05 | 2019-06-12 | 組成物およびスクリーニング方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019109634A Pending JP2019206528A (ja) | 2013-11-05 | 2019-06-12 | 組成物およびスクリーニング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9913857B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3065572B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6890972B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2014345344B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3028210C (cg-RX-API-DMAC7.html) |
| GB (2) | GB201319539D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015067949A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10633714B2 (en) | 2013-07-21 | 2020-04-28 | Pendulum Therapeutics, Inc. | Methods and systems for microbiome characterization, monitoring and treatment |
| GB201319531D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
| JP2018500048A (ja) * | 2013-11-05 | 2018-01-11 | オプティバイオティックス リミティド | プレバイオティック組成物及びその製造方法 |
| GB201319539D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
| GB2551642B (en) | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| GB201509023D0 (en) * | 2015-05-27 | 2015-07-08 | Optibiotix Ltd | Compositions and methods of production thereof |
| GB201509021D0 (en) * | 2015-05-27 | 2015-07-08 | Optibiotix Ltd | Methods of screening |
| WO2018023003A1 (en) * | 2016-07-29 | 2018-02-01 | Isothrive Llc | Optimized individualized prebiotic compositions |
| AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| EP4056052A1 (en) * | 2021-03-12 | 2022-09-14 | Biogaia AB | Gos pre-conditioning l. reuteri and gos in final formulation |
| EP4056053A1 (en) * | 2021-03-12 | 2022-09-14 | Biogaia AB | Pre-conditioning of l. reuteri |
| EP4554603A1 (en) * | 2022-07-12 | 2025-05-21 | Novozymes A/S | Method for providing relief from lactose induced abdominal discomfort |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE169456T1 (de) | 1996-12-23 | 1998-08-15 | Sitia Yomo Spa | Lyophilisierte, lebende bakerien enthaltende nahrungszusammensetzung |
| GB0303716D0 (en) * | 2003-02-18 | 2003-03-19 | Mars Uk Ltd | Food product and process |
| EP2035023A1 (en) | 2006-06-13 | 2009-03-18 | Nestec S.A. | Prevention and treatment of otitis media with non-pathogenic bacterial strains |
| US20080254011A1 (en) * | 2007-04-11 | 2008-10-16 | Peter Rothschild | Use of selected lactic acid bacteria for reducing atherosclerosis |
| BRPI0921617A2 (pt) | 2008-11-03 | 2015-08-18 | Nestec Sa | Composicao nutricional compreendendo probioticos e padroes do sono aperfeicoados |
| EP2216036A1 (en) | 2009-02-10 | 2010-08-11 | Nestec S.A. | Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control |
| PL2419114T5 (pl) * | 2009-05-01 | 2019-09-30 | Uas Laboratories Llc | Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej |
| US20110117629A1 (en) * | 2009-11-19 | 2011-05-19 | Family Medicine Interantional Co., Ltd. | Lactobacillus plantarum bb9 capable of adhering to gastrointestinal tract and cholesterol removal |
| ES2569241T5 (es) | 2010-01-19 | 2019-09-11 | Abbott Lab | Una composición que comprende Lactobacillus rhamnosus HN001 y prebióticos para su uso en el tratamiento de la enfermedad pulmonar alérgica |
| US20120263696A1 (en) | 2011-04-14 | 2012-10-18 | Stefan Roos | Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol |
| GB201319539D0 (en) * | 2013-11-05 | 2013-12-18 | Optibiotix Health Ltd | Composition & methods of screening |
-
2013
- 2013-11-05 GB GBGB1319539.1A patent/GB201319539D0/en not_active Ceased
-
2014
- 2014-11-05 JP JP2016551080A patent/JP6890972B2/ja active Active
- 2014-11-05 WO PCT/GB2014/053303 patent/WO2015067949A1/en not_active Ceased
- 2014-11-05 EP EP14806047.8A patent/EP3065572B1/en active Active
- 2014-11-05 CA CA3028210A patent/CA3028210C/en active Active
- 2014-11-05 AU AU2014345344A patent/AU2014345344B2/en active Active
- 2014-11-05 CA CA2929815A patent/CA2929815C/en active Active
- 2014-11-05 EP EP21153623.0A patent/EP3892116A1/en active Pending
- 2014-11-05 US US15/034,420 patent/US9913857B2/en active Active
-
2015
- 2015-05-05 GB GBGB1507664.9A patent/GB201507664D0/en not_active Ceased
-
2018
- 2018-02-21 US US15/901,637 patent/US10493093B2/en active Active
- 2018-07-26 AU AU2018208701A patent/AU2018208701B2/en active Active
-
2019
- 2019-06-12 JP JP2019109634A patent/JP2019206528A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537410A5 (cg-RX-API-DMAC7.html) | ||
| Gulliver et al. | the future of microbiome‐based therapeutics | |
| Centurion et al. | Nanoencapsulation for probiotic delivery | |
| Le Doare et al. | Mother’s milk: a purposeful contribution to the development of the infant microbiota and immunity | |
| Indira et al. | Bioactive molecules of probiotic bacteria and their mechanism of action: a review | |
| Venema | Intestinal fermentation of lactose and prebiotic lactose derivatives, including human milk oligosaccharides | |
| NZ601141A (en) | Nutritional formulas containing synbiotics | |
| NZ612386A (en) | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota | |
| JP2012520325A5 (cg-RX-API-DMAC7.html) | ||
| MY187609A (en) | Human milk oligosaccharides to ameliorate symptoms of stress | |
| JP2015523321A5 (cg-RX-API-DMAC7.html) | ||
| WO2012024638A3 (en) | Compositions and methods for treating obesity by characterizing and restoring mammalian bacterial microbiota | |
| PH12016501953A1 (en) | Pediatric nutritional composition with human milk oligosaccharides, prebiotics and probiotics | |
| WO2010146568A3 (en) | Bifidobacteria for treating diabetes and related conditions | |
| WO2014006261A3 (es) | Micropartículas para encapsulación de probióticos, su obtención y usos | |
| JP2016529309A5 (cg-RX-API-DMAC7.html) | ||
| CL2008001993A1 (es) | Uso de bacterias probioticas lactobacillus y bifidobacterium en la preparacion de una composicion para normalizar la concentracion de glucosa plasmatica, aumentar la respuesta a insulina y prevenir la diabetes gestacional. | |
| JP2017537156A5 (cg-RX-API-DMAC7.html) | ||
| FI3223838T3 (fi) | Kultakiivin koostumuksia ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| MY158816A (en) | Probiotics for reduction of risk of obesity | |
| JP2013139462A5 (cg-RX-API-DMAC7.html) | ||
| MX2009009442A (es) | Probioticos para mejorar la microbiota intestinal. | |
| MY172363A (en) | Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof | |
| JP2013177448A5 (cg-RX-API-DMAC7.html) | ||
| MX348937B (es) | Producto simbiotico. |